Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $10.0 million.

  • Organogenesis Holdings' Capital Expenditures fell 13.00% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 28.66%. This contributed to the annual value of $10.0 million for FY2024, which is 58.82% down from last year.
  • Latest data reveals that Organogenesis Holdings reported Capital Expenditures of $10.0 million as of FY2024, which was down 58.82% from $24.4 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Capital Expenditures ranged from a high of $33.9 million in FY2022 and a low of $10.0 million during FY2024.
  • In the last 3 years, Organogenesis Holdings' Capital Expenditures had a median value of $24.4 million in 2023 and averaged $22.8 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 195.42% in 2020, then plummeted by 58.82% in 2024.
  • Organogenesis Holdings' Capital Expenditures (MRY) stood at $17.7 million in 2020, then soared by 76.60% to $31.2 million in 2021, then rose by 8.58% to $33.9 million in 2022, then dropped by 28.13% to $24.4 million in 2023, then crashed by 58.82% to $10.0 million in 2024.
  • Its Capital Expenditures was $10.0 million in FY2024, compared to $24.4 million in FY2023 and $33.9 million in FY2022.